Search International and National Patent Collections
Some content of this application is unavailable at the moment.
If this situation persists, please contact us atFeedback&Contact
1. (WO2017134598) FOSTEMSAVIR FOR USE IN HEAVILY TREATMENT-EXPERIENCED HIV-1 INFECTED INDIVIDUALS
Latest bibliographic data on file with the International Bureau

Pub. No.: WO/2017/134598 International Application No.: PCT/IB2017/050571
Publication Date: 10.08.2017 International Filing Date: 02.02.2017
IPC:
A61K 31/46 (2006.01) ,A61K 31/496 (2006.01) ,A61K 31/505 (2006.01) ,A61K 31/5365 (2006.01) ,A61K 31/635 (2006.01) ,A61K 31/675 (2006.01) ,A61P 31/18 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
435
having six-membered rings with one nitrogen as the only ring hetero atom
46
8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
495
having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
496
Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
495
having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
505
Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
535
having six-membered rings with at least one nitrogen and at least one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
5365
ortho- or peri-condensed with heterocyclic ring systems
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
63
Compounds containing para-N-benzene- sulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonohydrazide
635
having a heterocyclic ring, e.g. sulfasalazine
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
66
Phosphorus compounds
675
having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31
Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
12
Antivirals
14
for RNA viruses
18
for HIV
Applicants:
VIIV HEALTHCARE UK (NO.5) LIMITED [GB/GB]; 980 Great West Road Brentford Middlesex TW89GS, GB
Inventors:
GRASELA, Dennis Michael; US
HANNA, George; US
KRYSTAL, Mark R.; US
LATAILLADE, Max; US
Priority Data:
62/291,30204.02.2016US
Title (EN) FOSTEMSAVIR FOR USE IN HEAVILY TREATMENT-EXPERIENCED HIV-1 INFECTED INDIVIDUALS
(FR) FOSTEMSAVIR POUR UTILISATION CHEZ DES SUJETS INFECTÉS PAR LE VIH-1 ET LOURDEMENT PRÉTRAITÉS
Abstract:
(EN) A method of attaining virologic suppression in a heavily treatment-experinced (HTE) individual infected with the HIV-1 virus involves administering to the individual a treatment regimen comprising the drug fostemsavir together with an optimized background therapy (OBT). This treatment regimen should maintain virologic suppression to a plasma HIV-1 RNA level of less than 200 copies (c)/mL for an extended period.
(FR) L'invention concerne un procédé permettant d'obtenir un contrôle virologique chez des sujets infectés par le VIH-1 et lourdement prétraités, lequel procédé consiste à administrer au sujet un schéma thérapeutique comprenant le médicament dénommé fostemsavir conjointement avec un traitement de fond optimisé. Ce schéma thérapeutique doit permettre de conserver un contrôle virologique tel à ce que le taux plasmatique d'ARN de VIH-1 reste inférieur à 200 copies (c)/mL pendant une période prolongée.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)
Also published as:
EP3411033US20190030025